Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

Lancet

Volumn 370, Issue 9590, 2007, Pages 829-840

  Patel, Anushka ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; SULFONYLUREA; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

EID: 34548420712     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61303-8     Document Type: Article

References (30)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes; estimates for year 2000 and projections for 2030. Diabetes Care 21 (2004) 1047-1053
2. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 165 (2005) 1410-1419
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
4. Strippoli G., Craig M., Schena F., and Craig J. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 17 (2006) S153-S155
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
6. Asia Pacific Cohort Studies Collaboration. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 25 (2007) 1205-1213
7. Gu D., Reynolds K., Wu X., et al. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension 40 (2002) 920-927
8. Ong K., Cheung B., Man Y., Lau C., and Lam K. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49 (2007) 69-75
9. Wolf-Maier K., Cooper R., Kramer H., et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43 (2004) 10-17
10. Mancia G., and Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 20 (2002) 1461-1464
11. Baker S., Priest P., and Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ 320 (2000) 680-685
12. Law M., Wald N., Morris J., and Jordan R. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326 (2003) 1427-1434
13. ADVANCE Management Committee. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl 19 (2001) S21-S28
14. Woodward M. Epidemiology: Study Design and Data Analysis. Second edition edn. (2005), Chapman and Hall/CRC Press, Boca Raton
15. Shulz K., and Grimes D. Multiplicity in randomised trials I: endpoints and treatments. Lancet 365 (2005) 1591-1595
16. Dahlof B., Sever P., Poulter N., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
17. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-258
18. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335 (1990) 827-838
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
20. Dagenais G., Pogue J., Fox K., Simoons M., and Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction of heart failure: a combined analysis of three trials. Lancet 368 (2006) 581-588
21. Danchin N., Cucherat M., Thuillez C., Durand E., Kadri Z., and Steg P. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction. Arch Intern Med 166 (2006) 787-796
22. Anavekar N., McMurray J., Velazquez E., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
23. Go A., Chertow G., Fan D., McCulloch C., and Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
24. Stolk R., Vingerling J., Cruickshank J., et al. Rationale and design of the AdRem study: Evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp Clin Trials 28 (2007) 6-17
25. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 26 (2003) 360-366
26. Kannel W., and McGee D. Diabetes and cardiovascular disease. The Framingham Study. JAMA 241 (1979) 2035-2038
27. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
28. Costa J., Borges M., David C., and Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 (2006) 1115-1124
29. Ambrosi P., Villani P., and Bouvenot G. Antiplatelet therapy for primary prevention in diabetes. Diabetes Metab 32 (2006) 2S52-2S56
30. Stettler C., Allemann S., Juni P., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152 (2006) 27-38